Based on the earnings transcript, Amgen's stock price is likely to experience a positive impact in the short term (1â€“2 weeks). The company reported strong Q2 financial results, with revenue growth of 11% year-over-year and EPS growth of 25%. Additionally, the company announced a restructuring plan that includes cost-cutting measures and a focus on strategic growth areas. This restructuring plan is expected to result in pretax accounting charges of $775 million to $950 million in 2014 and 2015, but the company expects to reinvest most of these savings in the business. Management also provided an optimistic outlook for the future, with guidance for 2014 revenue of $19.5 billion to $19.7 billion and adjusted EPS of $8.20 to $8.40. The stock is likely to rally in the short term due to these positive developments.

Rating: 2